NDC properties for "24 HR Androderm 0.0833 MG/HR Transdermal System" (RxCUI 1190955)
About this data
The tables show NDC propoerties for 24 HR Androderm 0.0833 MG/HR Transdermal System with the RxCUI 1190955
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for 24 HR Androderm 0.0833 MG/HR Transdermal System (RxCUI 1190955)
| MMSL_CODE | BD39855 |
|---|---|
| NDA | NDA020489 |
| RxCUI | 1190955 |
| SPL_SET_ID | e58a5328-fdd9-40cb-a19f-8ed798989b9c |
| Prescribable Synonym | ANDRODERM 2 MG/Day 24HR Transdermal System |
| RXNAV_STR | ANDRODERM 2 MG/Day 24HR Transdermal System |
| RxNorm Name | 24 HR testosterone 0.0833 MG/HR Transdermal System [Androderm] |
| RxNorm Synonym | 24 HR Androderm 0.0833 MG/HR Transdermal System |
| RxNorm Synonym | Androderm 2 MG per 24 HR Transdermal Patch |
| RxNorm Synonym | ANDRODERM 2 MG/Day 24HR Transdermal System |
| Related queries | Interactions (for RxCUI 1190955) |
NDC Properties
NDC Item 00023599002
| NDC 9 | 0023-5990 |
|---|---|
| NDC 10 | 0023-5990-02 |
| NDC Item | 00023599002 |
| DCSA | CIII |
| FDA SPL set id | 692017 |
| Labeler | Allergan, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2024-09-30 |
| Marketing effective time low | 1995-09-29 |
| Marketing status | COMPLETED |
| NDA | NDA020489 |
| Related queries | Properties for NDC 9 0023-5990 |
NDC Item 00023599060
| NDC 9 | 0023-5990 |
|---|---|
| NDC 10 | 0023-5990-60 |
| NDC Item | 00023599060 |
| Packaging | 60 POUCH in 1 CARTON (0023-5990-60) / 1 PATCH in 1 POUCH / 1 d in 1 PATCH |
| DCSA | CIII |
| FDA SPL set id | 692017 |
| Labeler | Allergan, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2024-09-30 |
| Marketing effective time low | 1995-09-29 |
| Marketing status | COMPLETED |
| NDA | NDA020489 |
| Related queries | Properties for NDC 9 0023-5990 |
NDC Item 00023599002
| NDC 9 | 0023-5990 |
|---|---|
| NDC 10 | 0023-5990-02 |
| NDC Item | 00023599002 |
| DCSA | CIII |
| FDA SPL set id | 692017 |
| Labeler | Allergan, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2024-09-30 |
| Marketing effective time low | 1995-09-29 |
| Marketing status | COMPLETED |
| NDA | NDA020489 |
| Related queries | Properties for NDC 9 0023-5990 |
NDC Item 00023599060
| NDC 9 | 0023-5990 |
|---|---|
| NDC 10 | 0023-5990-60 |
| NDC Item | 00023599060 |
| Packaging | 60 POUCH in 1 CARTON (0023-5990-60) / 1 PATCH in 1 POUCH / 1 d in 1 PATCH |
| DCSA | CIII |
| FDA SPL set id | 692017 |
| Labeler | Allergan, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2024-09-30 |
| Marketing effective time low | 1995-09-29 |
| Marketing status | COMPLETED |
| NDA | NDA020489 |
| Related queries | Properties for NDC 9 0023-5990 |